Objective: To investigate the feasibility of assessing the efficacy of manual lymphatic drainage (MLD), a method for lymphedema (LE) management, by using near-infrared (NIR) fluorescence imaging.
A
LTHOUGH ONE in 30 persons worldwide has LE, 1 management of this disease has escaped rigorous scientific investigation. LE as a result of cancer staging and treatment has an estimated incidence of up to 50% of all patients with breast cancer who undergo axillary lymph node dissection and radiation therapy 2 and up to 64% of patients with cancer undergoing groin or pelvic lymph node dissections. 3 A smaller but equally affected population of children and adults with congenital or hereditary lymphovascular defects also has LE. In the United States, there are several nonpharmacologic and nonsurgical treatments for LE, but as reported recently by Oremus et al 4 to the US Centers for Medicare & Medicaid Services, no study has shown sufficient evidence of benefit from any of these treatments. The accepted method to manage LE is through the use of CDT, which includes MLD, compression bandaging, therapeutic exercise, and meticulous skin care. Although its effectiveness is controversial, MLD is thought to first stimulate lymphatic drainage from receiving lymph node basins and then presumably stimulate contractile or "pumping" function of the superficial (epifascial) lymphatic system for subsequent drainage. 5 Response to MLD usually is measured indirectly through reduction of limb volume using a number of accepted and experimental methods over weeks to months. 6 Unfortunately, there is no method available to immediately evaluate the efficacy of MLD in a single treatment session. Although CDT response rates using limb volumetric measurements were reported to be 67.7% for patients with lowerextremity (LE) and 59.1% for those with upper-extremity LE over a management period of 12 months, 6 there is no method to (1) predict who will respond to CDT or (2) measure whether No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit on the authors or on any organization with which the authors are associated.
Correspondence to Eva M. Lymphoscintigraphy is the only accepted imaging approach for the diagnosis of lymphatic transport dysfunction through quantifying the transit time of radionuclide transport from a distal injection site to the draining lymph node basins, its clearance from the injection site, or its accumulation in draining lymph nodes. 7 Magnetic resonance imaging 8 and computed tomography 9 also are used when lymphoscintigraphy is not available. Insufficient spatial and temporal resolutions of these imaging modalities, as well as lack of contrast agent clearance, do not allow pre-and post-MLD imaging in a single therapy session to provide efficient evaluation of LE treatment. 10 Recently, we developed an investigational technique of NIR fluorescence imaging that has tenths-of-second temporal resolution to visualize the active contractile function and architecture of human lymphatics. 11 Because a fluorophore can be excited repeatedly to provide significant photon count rates, in vivo human imaging can be accomplished by using microdose administration of fluorescent contrast agent. 12 Marshall et al 13 provided an extensive review of several studies using NIR optical imaging devices and ICG to map the lymphatics in humans. Previously, we 11 and others 14 showed that the architecture and contractile function of lymphatics can be visualized directly to show differences in lymph transport between normal limbs of control subjects, asymptomatic limbs of subjects with LE, and symptomatic limbs of subjects with LE. 15, 16 Differences in lymphatic contractile function were quantified by using (1) the apparent propulsive lymph velocities and (2) period or time of arrival between successive propulsive events.
This was the first study of NIR fluorescence imaging to assess lymphatic contractile function in humans. No other imaging modality exists to provide quantifiable metrics of lymphatic (dys)function.
A feasibility study was designed to test the hypothesis that NIR fluorescence imaging could quantitatively evaluate responses of lymphatic contractile function pre-and post-MLD in healthy control subjects and persons with a clinical diagnosis of extremity LE. We sought to determine whether NIR fluorescence imaging could be used to evaluate the effectiveness of MLD immediately after a single therapy session.
METHODS

Study Design
The protocol used for this exploratory pilot study was approved under a combinational exploratory investigational new drug application for the off-label use of ICG as an NIR fluorescent contrast agent. The Health Insurance Portability and Accountability Act-compliant studies were approved by the Institutional Review Board at Baylor College of Medicine, where the trials were conducted, and at the University of Texas Health Science Center, where imaging data were analyzed. This pilot study was limited to determine the feasibility of using NIR fluorescence imaging to assess response to MLD. Twelve healthy volunteers and 10 subjects with a clinical diagnosis of grade I or II unilateral LE participated and provided informed consent. All subjects received MLD therapy. Detailed demographics and causes of disease in these subjects are listed in table 1. 
NIR Fluorescence Imaging
The imaging contrast agent, ICG, was reconstituted in water and diluted in saline solution to a concentration of 0.25mg/mL. Each subject received intradermal injections of 0.1mL each using 29-gauge needles for a maximum total dose of 400g of ICG. Injection sites were symmetrical on contralateral limbs. The maximum number of injections was 6 in each arm and 8 in each leg. Generally, 2 injections were made on the dorsum of the hand, 2 on the medial forearm, and 2 on the lateral forearm when arms were imaged. When imaging legs, 2 injections were made in the dorsum of the foot, 2 on the medial ankle, 1 on the heel, 2 on the calf, and 1 on the thigh. Subjects were given the option to receive topical anesthetic with lidocaine 2.5% and prilocaine 2.5% cream applied directly to the injection site to lessen the injection sensation because prior work showed no difference in measurements with and without topical anesthetic. 15 All subjects were asked whether they wished to decline further injections in the event they found the first injections uncomfortable. Immediately after injections, the location and movement of ICG in the lymphatics were imaged simultaneously in both limbs by using 2 custom-built fluorescence imaging systems. Details of the imaging systems can be found elsewhere, 15 but in brief, each system consisted of an excitation light source, holographic and band-pass filters, NIR-sensitive image intensifier, and customized charge-coupled device camera. Sequential fluorescence images were acquired by using a 200-ms camera integration time permitting near-real-time imaging of the lymphatics. Subjects remained supine on a bed during imaging. After ICG administration, subjects underwent imaging first for 30 to 60 minutes, then MLD was performed for 23 to 28 minutes with concurrent imaging. Imaging continued 30 to 60 minutes after the finish of MLD. No adverse events were associated with the imaging agent or device in this study. Apparent lymph velocities and propulsion periods were calculated from the imaging data.
15
Manual Lymphatic Drainage
MLD was performed on bare skin by a certified LE therapist; neither oils nor lotions were used during MLD therapy. MLD consisted of gentle massage to the cervical lymph nodes for 3 minutes, followed by massage to the axillary and inguinal nodes for 5 minutes in the preparation period. In subjects with arm LE, the areas treated with massage were the neck, followed by the axillary region on the contralateral (asymptomatic) arm and the ipsilateral (symptomatic side) inguinal region. For subjects with leg LE, the procedure consisted of massage at the neck followed by treatment of the contralateral inguinal nodes and ipsilateral axillary lymph nodes. For control subjects, after massage to the neck for 3 minutes, massage was performed at the bilateral axillary regions for 5 minutes if the arms were imaged or at the bilateral inguinal regions if the legs were imaged.
After this preparation period, the limbs being imaged were massaged with centripetal light strokes starting at the proximal aspect of the limb, following with more distal segments. For the arms, the MLD protocol for both controls and subjects with LE was conducted in the following order: (1) 5 minutes on the upper arm, (2) 5 minutes on the forearm, and (3) 5 minutes on the hand. Similarly for the legs, the order was (1) 5 minutes on the thigh, (2) 5 minutes on the leg, and (3) 5 minutes on the foot. Live fluorescence images of lymphatic architecture were available to therapists during MLD to provide guidance for massage. Images collected before MLD were classified as pre-MLD, and the data after, as post-MLD results. Apparent lymph velocity and periods between successive propulsions of Abbreviations: Asym, asymptomatic; Symp, symptomatic.
*Evaluated using linear mixed model for repeated measurements.
lymph were computed from the movement of fluorescent packets in images as in a previous study.
15
Statistical Analysis Statistical analysis of the apparent velocities and propulsion periods computed from the images was performed using MATLAB a and SAS.
b Each propulsion of ICG-laden lymph was assumed to be an independent event for a given subject, and distributions of apparent velocities and propulsion periods were assumed to be log-normal. Although a larger clinical trial will enable determination of whether the latter assumption is correct, this assumption alleviated data skewness and made observations more symmetric. The Kolmogorov-Smirnov test indicated that at least half the subjects had apparent velocities and propulsion periods follow the normal distribution after log-transformation, and the rest did not have a small enough P value for rejection of normality. ANOVA of logarithm-transformed data was performed to determine the relationship of lymphatic functions between pre-and post-MLD for different diagnoses (control, symptomatic, asymptomatic) and limbs (arm, leg). For data from each subject, paired t tests were performed to investigate the effect of MLD on each side (right or left for control subjects, symptomatic or asymptomatic for subjects with LE). For studywide analysis, data were pooled by groups of interest (ie, all asymptomatic arm data vs all symptomatic arm data) to investigate differences between groups. Because of the nature of correlated observations of apparent velocities and propulsion periods within subjects, analyses using linear mixed models for repeated measurements were performed. For all analyses, the tested factor was determined to be significant at P less than .05.
RESULTS
Because this was an exploratory pilot study, sample size was limited and not powered for statistical testing. Nonetheless, although comprehensive comparisons were not intended, our data provided sufficient numbers for partial evaluation. Specifically, we found statistically significant differences pre-and post-MLD in healthy subjects and subjects with LE, as well as trends of improved lymph transport post-MLD that suggest (1) the benefit of MLD and (2) the use of investigational NIR fluorescence imaging to potentially provide direct evidence of benefit from MLD in subjects with LE within a single therapy session. Statistics for lymph function in arms and legs for pooled data are listed in table 2. Next, we present results detailing the effect of MLD in both arms and legs of healthy subjects and subjects with LE. 
Effect of MLD in Arms
Images of lymphatics show striking differences in lymphatic vasculatures between control limbs and symptomatic and asymptomatic LE limbs, similar to that observed in our previous study. 15 Lymphatic structure in limbs of healthy subjects generally consists of well-defined channels that actively propel and drain lymph into the regional nodal basins. In contrast, the lymphatic structure of symptomatic limbs of subjects with LE typically shows capillary networks, tortuous vessels, or extravascular lymphatic fluid leakage. Figure 1A shows a fluorescence image obtained from the control arm of subject NA12 when a gentle massage stroke of MLD was performed on the right forearm. Figure 1B shows the fluorescent image obtained 9.3 seconds after the massage stroke. All images presented here are in pseudo-color. A wave of fluorescent lymph "packets" (indicated by arrows) was observed in multiple vessels moving toward axillary lymph nodes. Abbreviated and example compilations of these images are shown in supplemental videos 1 and 2 (available at the Archives website: www.archives-pmr.org). Supplemental video 3 (also available at the Archives website: www.archivespmr.org) shows a similar image sequence recorded during MLD on the symptomatic arm of subject LA03 with LE. All videos are played approximately 3 times faster than real time. From the full-length image sequences exampled, values of apparent lymph velocity and propulsion periods were determined.
Averages of pre-and post-MLD apparent lymph velocities and propulsion periods obtained from symptomatic and asymptomatic arms of 5 subjects with LE and normal (both right and left) arms of 6 control subjects are shown in fig 2. Significant differences (PϽ.05) between the velocities or periods measured pre-and post-MLD within each subject are marked with asterisks. In healthy control subjects, 5 of 6 subjects experienced trends of increased apparent lymph velocities after MLD, with 3 of 5 subjects experiencing statistically significant differences in 1 or both arms. Of 6 healthy subjects, 4 experienced trends of decreased propulsive periods (or increased propulsive frequencies) after MLD, indicating improved lymphatic transport. Of these 4 healthy subjects, 2 showed statistically significant improvement in propulsive periods. It is noteworthy that, as expected, there was no statistically significant decrease in lymphatic transport (ie, decrease in apparent lymph velocity or increase in propulsive period) in healthy subjects. However, 1 subject (NA11) tended to have changes that indicate a decrease in lymphatic transport after MLD (ie, decrease in apparent velocity and increase in propulsive period), suggesting the variability in MLD effectiveness reported in the literature. These results show that future clinical trials need to be designed to assess whether individual variability in the immediate response to MLD in a healthy population and within a single session mimics the variability similarly assessed in well-defined LE populations. In the LE group, average apparent lymph velocity in all asymptomatic arms increased after MLD, with 1 showing a statistically significant increase. In the 4 of 5 symptomatic arms that showed propulsive lymphatic function, 2 showed increased average apparent lymph velocity after MLD, although the other 2 showed a decrease in apparent velocity. The asymptomatic arm of subject LA04 and the symptomatic arm of subject LA05 showed statistically significant increases in propulsion periods, whereas the symptomatic arm of subject LA04 showed statistically significant decreases in the propulsive period after MLD, indicative of improvement in lymphatic transport. Two of 5 subjects with LE (LA04, LA06) experienced improved function, indicated by the increase in apparent velocity and decrease in propulsive period in symptomatic arms after MLD. It is noteworthy that subject LA06 was clinically responsive to intensive MLD and bandaging. In this subject, the volume of the afflicted arm decreased by 15% after every first week of three 6-week LE treatment sessions.
No propulsion was found in symptomatic arms of subject LA01 or LS03, implying the ineffectiveness of MLD. Dermal backflow was observed in both these subjects' hands, providing possible speculation for the clinically demonstrated failure of MLD effectiveness in the management of their disease. Subject LA01 was clinically unresponsive to intensive MLD and bandaging conducted over 6 weeks.
Statistical results of the pooled data grouped into symptomatic, asymptomatic, and control arms are shown in fig 3. Average apparent lymph velocities and propulsion periods are plotted for each group, with percentages of change from pre-to post-MLD indicated. Apparent lymph velocities show trends of increase for all groups after MLD, and the increases were statistically significant in asymptomatic and control arms using the linear mixed model (see table 2 ). The periods show trends of decrease for all groups, and the decrease for the control arm group was statistically significant. Overall, our results showed a significant increase in apparent velocity and decrease in period after MLD on arms. Figure 1C shows a fluorescence image obtained from the symptomatic leg of subject LL07 when MLD was performed on the foot. Figure 1D shows the image obtained 2.8 seconds afterward. Lymph in a vessel was observed being pushed toward the ankle due to the massage strokes. The compilation of these images is shown in supplemental video 4 (available at the Archives website: www.archives-pmr.org). Also, the enhanced lymphatic contractile function of a symptomatic leg during MLD is shown in supplemental video 5 (available at the Archives website: www.archives-pmr.org).
Effect of MLD in Legs
Averages of pre-and post-MLD apparent lymph velocities and propulsion periods obtained from symptomatic and asymptomatic legs of 5 subjects with LE and control legs of 6 healthy subjects are shown in fig 4. In 10 of 12 control legs, there was an increase in average apparent velocity after MLD, with 5 showing statistically significant increases. The periods showed a statistically significant decrease after MLD in 4 control legs, indicating improvement in lymphatic function after MLD.
In this feasibility study, none of the symptomatic legs showed a statistically significant change in apparent lymph velocity after MLD, and 1 asymptomatic leg (subject LL02) showed a significant decrease in apparent lymph velocity. None of the legs of subjects with LE showed significant changes in propulsion periods. However, 3 subjects with LE (LL02, LL06, LL07) experienced trends of improved function through an increase in average apparent velocity and/or decrease in average propulsion period in symptomatic legs. It is noteworthy that subject LL02 was clinically responsive to intensive MLD and bandaging. The afflicted limb of subject LL02 showed more than a 12% volume decrease after the first week of a 4-week LE treatment session. LE subject LL01 was not clinically responsive to MLD, and no lymph propulsion was found in the symptomatic leg, but a single lymph vessel, which was not seen before MLD, was recruited for transiting ICG to the trunk.
Statistical results of the pooled data grouped into symptomatic, asymptomatic, and control legs are shown in fig 5. Average apparent lymph velocities and propulsion periods are plotted for each group, and percentages of change from pre-to post-MLD are indicated. Apparent lymph velocities show trends of increase for all groups after MLD, and the increases were statistically significant in control legs (see table 2 ). Propulsion periods show trends of decrease in asymptomatic and control legs, but are not statistically significant. Overall, the results show statistically significant increases in apparent velocity and trend of decrease in periods after MLD on legs.
For statistical analysis, results of the pooled data from all 22 subjects (44 limbs) in the study, ANOVA indicated that MLD improved lymphatic contractile function, as reported by increases in apparent velocities in all limb diagnoses (symptomatic, ϩ23%; Pϭ.24; asymptomatic, ϩ25%; Pϭ.007; control,ϩ28%; PϽ.001) and also by decreases in propulsion periods (symptomatic, Ϫ8.6%; Pϭ.37; asymptomatic, Ϫ20%; Pϭ0.7; control, Ϫ23%; Pϭ.007). 
DISCUSSION
MLD is hypothesized to stimulate lymphatic contractile function and promote the clearance of lymph fluid from the affected area. 17 However, some patients with LE do not benefit from MLD and there is a need to provide an imaging tool to predict a patient's benefit from MLD. Medicare reimbursement policies require clinical demonstration of MLD ineffectiveness before certain classes of PCDs can be prescribed to replace or augment MLD. Such prognostic tools could improve patient compliance, which is most cited as the leading cause of failure of MLD, 18 and more efficiently enable the prescription of replacement or augmented therapies.
NIR fluorescence imaging allowed us not only to visualize the lymphatic structures, but also to assess contractile function by measuring apparent lymph velocity and period of propulsion. By evaluating differences in lymphatic architecture in different diagnosed (symptomatic, asymptomatic, healthy control) limbs and lymphatic contractile function in response to MLD, we sought to assess the effect of MLD on lymphatics in this phase 0 exploratory pilot study to establish the feasibility of NIR fluorescence lymphatic imaging.
Depending on the severity of disease, the numbers of functional lymphatic vessels can vary within different regions of the afflicted limb. By directing lymphatic drainage toward existing functional lymphatic structures, improved responses to MLD could result. 19 The importance of existing lymphatic vasculature in MLD treatment of early disease is supported by the studies of McNeely et al, 20 who found that patients with mild breast cancer-related LE had significantly larger relative volume decreases after treatment than those with severe LE. Functioning lymphatic vessels that transport lymph toward major lymph node basins may be necessary for patients with LE to optimally benefit from MLD. Using NIR fluorescence imaging to find functioning lymphatics, manually guide drainage toward them, and treat patients earlier, more effective MLD potentially could result. We showed that in 10 subjects with LE, 2 (LA04, LA06) of 5 symptomatic arms and 3 (LL02, LL06, LL07) of 5 symptomatic legs showed improved lymphatic function in terms of increased apparent velocity and/or decreased propulsion period after MLD, suggesting that MLD is a viable treatment for LE in these subjects. NIR fluorescence imaging could provide guidance for personalized care.
However, stimulation of contractile function in the symptomatic limbs was quantitatively not as large as that obtained in control limbs, possibly because of the lack of organized lymphatic networks associated with the advancing stage of subjects with LE, which was not controlled for in this pilot study. 21 Capillary networks and tortuous vessels in patients with LE may cause high-resistance lymph drainage pathways that impede lymph flow, 18 even under MLD stimulation. These highresistance drainage pathways may characterize progressive LE and could prevent interstitial fluid from entering collecting vessels, resulting in the extravascular ICG-laden lymphatic fluid commonly seen in symptomatic limbs in our studies. The response of lymphatic parameters of velocity and period to MLD in asymptomatic limbs also was decreased in comparison to control limbs. This result is supported by the abnormal lymphatic architecture observed in asymptomatic limbs and the recent evidence of a systemic or genetic predisposition for acquired lymphedema after surgery or trauma. 22 It also may be noteworthy that only the control-limb group showed significant decreases in propulsion period after MLD. If partial or complete loss of lymphatic contractile function is associated with progressive lymphedema, 21 stimulation with MLD may be expected to cause a diminished impact on the frequency of lymph propulsion in subjects with LE compared with healthy control subjects.
These studies could suggest the feasibility of using NIR fluorescence imaging to evaluate the effectiveness of MLD in a single session. The results contained here may be used to properly power a clinical study to assess both the immediate and long-term benefit of MLD for patients with LE. NIR lymphatic fluorescence imaging may provide a means to assess best management practices for LE, whether manual physical therapies, such as MLD, PCD, 16 and microsurgery, or new pharmacologic targets to reverse disease progression.
Study Limitations
There are study limitations associated with this phase 0 exploratory and pilot study.
The limited number of subjects intentionally did not allow for design of a study, but provided information to sufficiently power future clinical trials for reaching statistical conclusions that may translate into clinical practice. One could speculate from results of this study that legs respond better to MLD than arms and that some subjects benefit more than others. This idea must be borne out in a properly powered longitudinal study of MLD effectiveness. The mechanisms governing therapeutic response could involve the cause, degree of damage in lymphatics, and stage of the disease, all of which are not controlled in this study. The diversity in cause of disease and staging in subjects, as well as the protocol design that could not benefit from prior knowledge, limited this feasibility study. As a consequence, it might be expected that the different responses to MLD for subjects with various disease stage and cause could not be studied. Due to the limited number of study subjects, the lack of significance of metrics probably results from insufficient power. In addition, our assumption of normality of the apparent velocities and propulsion periods for ANOVA and paired t test require further investigation for properly powered studies. Nonetheless, results show the effectiveness of MLD after a single session and suggest a clinical trial designed to statistically address the use of NIR fluorescence imaging metrics for individualized prediction of LE treatment response. Future protocols to acquire sufficient data for evaluating differences pre-and post-MLD within individual patients could lead to personalized care of patients with LE.
Another inherent study limitation was the lack of independent criterion-standard techniques to validate (1) lymphatic contractile activity and (2) depth of the functional lymphatics imaged by using NIR fluorescence imaging. As described here and elsewhere, 12 no other imaging technique exists with the temporal discrimination to visualize contractile activity, which is proposed to be stimulated by MLD. Even so, the approved imaging of lymphatics using lymphoscintigraphy is not amenable for pre-and posttreatment imaging within a single therapy session, as is NIR fluorescence imaging. Finally, another limitation inherent to this pilot study may be the insufficient information and mismatched resolution to coregister planar NIR fluorescence imaging with the only other approved lymph imaging approach of planar lymphoscintigraphy to assess the depth of lymphatic vessels imaged. While we are developing unique dual-labeled imaging agents for positron emission tomography and NIR fluorescence tomography 23, 24 to validate the depth of NIR signal origin, estimates for NIR fluorescence have ranged as high as 4 to 5cm. 25 The depth to which lymphatics can be imaged by using NIR fluorescence imaging in these studies is unclear. Nonetheless, we speculate that lymphatics within a few centimeters of the tissue surface were visualized and our results may not include the response of deep lymphatic beyond the epifascial lymphatics that MLD treatment focused on improving.
CONCLUSIONS
We showed that NIR fluorescence imaging could be used to quantitatively assess lymphatic propulsion after MLD due to (1) the temporal resolution that enables visualization of contractile function, (2) the ability to track lymphatic parameters pre-and posttherapy within the same session, and (3) the unique quantification of apparent lymph velocity and propulsion period owing to contractile lymphatic transport function. Results of this exploratory pilot study not only show that contractile lymphatic function improved after a single session of MLD in some subjects, but also the feasibility for using NIR fluorescence imaging to monitor response to treatment. Further studies are needed to confirm the prognostic clinical capabilities of NIR fluorescence lymph imaging to assess best management practices for LE. 
